Is it safe to deliver SBRT to progressive lung metastases to patients with metastatic RCC receiving concurrent pazopanib?

Topics: Radiation Oncology • Palliation • Genitourinary Cancers • Thoracic Malignancies • Stereotactic Body Radiotherapy • Medical Oncology

Answer from: Radiation Oncologist at Academic Institution

Generally speaking, yes, it’s safe with some caveats. Pazopanib is a bit of a “dirty” TK inhibitor and so has some VEGF inhibition. That has some implications if you are treating close to hollow viscous like the esophagus, stomach (if on the diaphragm) or trachea. If it...

Comments

Radiation Oncologist at Center for Neurosciences
I just had a case of oligometastatic RCC on Pazopa...

Radiation Oncologist at Center for Neurosciences
I should say, too, that we treated 50/5 QOD as wel...

Radiation Oncologist at Mayo Clinic
PET is notoriously unhelpful after SBRT. Some use...

Medical Oncologist at Stanford University Medical Center
I agree with this as well.

Answer from: Medical Oncologist at Academic Institution

In our practice it has been safe to deliver SBRT to lung metastases while receiving drugs such as pazopanib given the thought that SBRT is more directed and associated with lower rates of pneumonitis.

Related Questions